نتائج البحث - Michael Arbushites

  • يعرض 1 - 9 نتائج من 9
تنقيح النتائج
  1. 1
    Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH Trials

    Ruxolitinib for the Treatment of Patients with Steroid-Refractory GVHD: An Introduction to the REACH Trials حسب Madan Jagasia, Robert Zeiser, Michael Arbushites, Patricia Delaite, Brian Gadbaw, Nikolas von Bubnoff

    منشور في 2018
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer

    Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomize... حسب Richard S. Finn, Michael F. Press, Judy Dering, Michael Arbushites, María Koehler, Cristina Oliva, Lisa S. Williams, Angelo Di Leo

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study

    Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study حسب Leonardo Tenori, Catherine Oakman, Wederson M. Claudino, Patrizia Bernini, Silvia Cappadona, Stefano Nepi, Laura Biganzoli, Michael Arbushites, Claudio Luchinat, Ivano Bertini, Angelo Di Leo

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens

    Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens حسب Kimberly Blackwell, Mark D. Pegram, Elizabeth Tan-Chiu, Lee S. Schwartzberg, Michael Arbushites, Julie Maltzman, John Forster, S. D. Rubin, Steven H. Stein, Harold J. Burstein

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

    Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer حسب Angelo Di Leo, Henry Gómez, Zeba Aziz, Zanete Zvirbule, José Bines, Michael Arbushites, Stephanie Guerrera, María Koehler, Cristina Oliva, Steven H. Stein, Lisa S. Williams, Judy Dering, Richard S. Finn, Michael F. Press

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

    Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial حسب Madan Jagasia, Miguel‐Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi‐Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael Arbushites, Chuan Tian, Laura Connelly‐Smith, Michael Howell, H. Jean Khoury

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

    Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer حسب Henry Gómez, Dinesh Chandra Doval, Miguel A. Chavez, Peter Ang, Zeba Aziz, Shona Nag, Christina Ng, Sandra Franco, Louis W.C. Chow, Michael Arbushites, Michelle Casey, Mark S. Berger, Steven H. Stein, George W. Sledge

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

    HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer حسب Michael F. Press, Richard S. Finn, David Cameron, Angelo Di Leo, Charles E. Geyer, Ivonne Villalobos, Angela Santiago, Roberta Guzman, Armen Yuri Gasparyan, Yanling Ma, K. D. Danenberg, Anne Marie Martin, Lisa Williams, Cristina Oliva, Steven Stein, Robert Gagnon, Michael Arbushites, María Koehler

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease

    A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease حسب Mark A. Schroeder, H. Jean Khoury, Madan Jagasia, Haris Ali, Gary J. Schiller, Karl Staser, Jaebok Choi, Leah Gehrs, Michael Arbushites, Ying Yan, Peter Langmuir, Nithya Srinivas, Michael A. Pratta, Miguel‐Angel Perales, Yi‐Bin Chen, Gabrielle Meyers, John F. DiPersio

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: